Skip to content
BiologicalX

Comparison

Magnesium Glycinate vs Sermorelin

Side-by-side of Magnesium Glycinate and Sermorelin. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

Magnesium Glycinate

  • Shortens sleep onset latency in older adults and in deficient populations supplementing 200 to 400 mg elemental Mg
  • Improves subjective sleep quality scores (PSQI, ISI) modestly versus placebo over 4 to 8 weeks
  • Reduces nocturnal leg cramps and exercise-induced muscle cramping in some controlled trials
  • Lowers self-reported anxiety in mild-to-moderate cases, with smaller effect than first-line pharmacotherapy
  • Glycinate form delivers fewer GI side effects than oxide or citrate at equivalent elemental doses
  • Insufficient as a stand-alone hypertension treatment; small adjunctive blood-pressure reductions only

Sermorelin

  • Synthetic 29-amino-acid GHRH fragment; FDA approved 1997 for pediatric GH deficiency as Geref
  • Voluntarily discontinued by Serono in 2008 for commercial reasons; not safety-related
  • Compounded by 503A/503B pharmacies for off-label adult anti-aging and body-composition use
  • Produces physiologic pulsatile GH release; ~10 to 20 minute plasma half-life
  • Standard anti-aging clinic protocol: 200 to 500 mcg subcutaneously pre-bed, often with ipamorelin
  • Banned by WADA under S2 (peptide hormones, growth factors)

Side-by-side

Attribute Magnesium Glycinate Sermorelin
Category supplement peptide
Also known as magnesium bisglycinate Sermorelin acetate, GRF 1-29, Geref, GHRH (1-29) NH2
Half-life (hr) 5 0.25
Typical dose (mg) 300 0.3
Dosing frequency daily (often evening) 1-2x daily
Routes oral subcutaneous
Onset (hr) 1 0.25
Peak (hr) - 0.5
Molecular weight - 3357.88
Molecular formula - C149H246N44O42S
Mechanism Magnesium acts as a cofactor for 300+ enzymes and as a voltage-dependent antagonist at NMDA receptors; glycine serves as an inhibitory neurotransmitter and co-agonist at glycine receptors. Synthetic 29-amino-acid GHRH fragment that binds the GHRH receptor on pituitary somatotrophs to stimulate endogenous pulsatile GH synthesis and release while preserving the GH-IGF-1 negative feedback loop.
Legal status Dietary supplement FDA approved 1997 (Geref, pediatric GHD); voluntarily discontinued by Serono 2008; compounded by 503A/503B pharmacies for off-label adult use; banned by WADA
WADA status allowed banned
DEA / Rx OTC supplement Rx only via compounding (no controlled-substance schedule)
Pregnancy Generally considered acceptable at RDA doses; consult clinician Category C (historical labeling); not recommended in pregnancy
CAS 14783-68-7 86168-78-7
PubChem CID 84645 16129617
Wikidata - Q416620

Safety profile

Magnesium Glycinate

Common side effects

  • mild GI upset at high doses
  • loose stools (dose-dependent, less than with oxide/citrate forms)

Contraindications

  • severe renal impairment
  • myasthenia gravis
  • heart block

Interactions

  • tetracycline and fluoroquinolone antibiotics: magnesium chelates antibiotic, reducing absorption; separate by 2+ hours(moderate)
  • bisphosphonates: reduced absorption of bisphosphonate(moderate)
  • potassium-sparing diuretics: possible hypermagnesemia in renal impairment(moderate)

Sermorelin

Common side effects

  • injection-site pain or irritation
  • transient flushing
  • headache
  • vivid dreams (pre-bed dosing)

Contraindications

  • pregnancy
  • active malignancy
  • history of pituitary tumor
  • diabetic retinopathy (theoretical)
  • untreated hypothyroidism

Interactions

  • ipamorelin: synergistic GH release via parallel GHRH and ghrelin pathways; standard anti-aging clinic pairing(minor)
  • CJC-1295: pharmacologically redundant (both GHRH-pathway); typically not stacked(minor)
  • insulin: sustained GH can blunt insulin sensitivity over weeks(moderate)
  • corticosteroids: blunt GH response; reduce expected efficacy(moderate)
  • levothyroxine (untreated hypothyroidism): untreated hypothyroidism blunts GH response; correct thyroid first(moderate)

Which Should You Take?

Magnesium Glycinate comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. Sermorelin is the right call when one of the conditionals below applies.

Edge case: If you want to avoid FDA approved 1997 (Geref, pediatric GHD); voluntarily discontinued by Serono 2008; compounded by 503A/503B pharmacies for off-label adult use; banned by WADA, Magnesium Glycinate is the more accessible choice.

Default choice: Magnesium Glycinate. Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Sermorelin only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between Magnesium Glycinate and Sermorelin?

Magnesium Glycinate and Sermorelin differ in category (supplement vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, Magnesium Glycinate or Sermorelin?

Magnesium Glycinate half-life is 5 hours; Sermorelin half-life is 0.25 hours.

Can you stack Magnesium Glycinate with Sermorelin?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper